Medical technology company Imperative Care announced it initially closed an oversubscribed Series E financing round led by Ally Bridge Group. The company says additional closings of the round could bring its Series E up to $150 million.
Existing investors AMED Ventures, D1 Capital Partners, Rock Springs Capital Management, Bain Capital Life Sciences, Pura Vida Investments and Innovatus Capital Partners participated in the round.
New investors Catalio Capital Management, HealthCor Family Office, INTAI Technology Corp and Montreux Growth Partners also contributed funds.
The company also announced the appointment of Shacey Petrovic as vice chair of its board of directors.
Imperative Care develops technology focused on addressing gaps in treatment for individuals who have had a stroke and other vascular diseases.
Its Kandu Health digital health platform offers remote patient monitoring and support services to help patients transition from the hospital to their homes following a stroke.
“We are grateful for the continued support of our existing investors and welcome our new investors who share our vision for leadership in stroke and vascular thrombectomy,” Fred Khosravi, chairman and CEO of Imperative Care, said in a statement.
“This latest financing fuels our hypergrowth strategy as we work to make better care accessible to more patients. We will continue to invest in novel technologies and clinical evidence to measure the impact of these technologies on patient outcomes.”
Tel Aviv-based startup Scopio Labs, which offers an AI-enabled digital cell morphology analysis platform, secured $42 million in Series D funding, bringing its total raise to $130 million.
Fortissimo Capital led the round, with participation from existing investors.
Scorpio Labs uses computational photography and AI to obtain and analyze digital images of thousands of blood cells. The company says the results can support clinical decisions to bolster patient care.
The company will use the funds to enhance its digital morphology platform and expand its global footprint.
“Scopio is experiencing a defining inflection point. The company’s hematology solutions are transforming the manner in which labs analyze blood samples. We believe Scopio Labs will become the new global standard in digital cell morphology,” Yuval Cohen, managing partner at Fortissimo Capital, said in a statement.
“We look forward to supporting Scopio as it grows and enhances its leading position in the market.”
Health robotics company NAVIGANTIS, which developed a robotic platform for neurovascular procedures, announced the close of a $12 million Series A financing round led by Puma Venture Capital.
Cormorant Asset Management, Mirae Asset Capital and all existing investors participated in the round.
Amit Hazan, founder and managing partner at Puma Venture Capital, will join the company’s board of directors.
The company will use the funds to continue developing and testing its VASCO robot and study it in clinical trials for neurovascular procedures.
